- Home
- SKIN vs NVRO Comparison
SKIN vs NVRO Comparison
Compare SKIN & NVRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- NVRO
- Stock Information
- Founded
- SKIN 1997
- NVRO 2006
- Country
- SKIN United States
- NVRO United States
- Employees
- SKIN N/A
- NVRO N/A
- Industry
- SKIN Package Goods/Cosmetics
- NVRO Medical/Dental Instruments
- Sector
- SKIN Consumer Discretionary
- NVRO Health Care
- Exchange
- SKIN Nasdaq
- NVRO Nasdaq
- Market Cap
- SKIN 207.3M
- NVRO 214.2M
- IPO Year
- SKIN N/A
- NVRO 2014
- Fundamental
- Price
- SKIN $1.61
- NVRO $5.73
- Analyst Decision
- SKIN Hold
- NVRO Hold
- Analyst Count
- SKIN 5
- NVRO 12
- Target Price
- SKIN $2.55
- NVRO $7.24
- AVG Volume (30 Days)
- SKIN 403.4K
- NVRO 1.7M
- Earning Date
- SKIN 03-07-2025
- NVRO 02-28-2025
- Dividend Yield
- SKIN N/A
- NVRO N/A
- EPS Growth
- SKIN N/A
- NVRO N/A
- EPS
- SKIN N/A
- NVRO N/A
- Revenue
- SKIN $347,620,000.00
- NVRO $419,146,000.00
- Revenue This Year
- SKIN N/A
- NVRO N/A
- Revenue Next Year
- SKIN $1.79
- NVRO $0.23
- P/E Ratio
- SKIN N/A
- NVRO N/A
- Revenue Growth
- SKIN N/A
- NVRO N/A
- 52 Week Low
- SKIN $0.91
- NVRO $3.17
- 52 Week High
- SKIN $5.17
- NVRO $16.12
- Technical
- Relative Strength Index (RSI)
- SKIN 47.61
- NVRO 70.16
- Support Level
- SKIN $1.51
- NVRO $4.77
- Resistance Level
- SKIN $1.74
- NVRO $5.80
- Average True Range (ATR)
- SKIN 0.09
- NVRO 0.13
- MACD
- SKIN -0.00
- NVRO -0.01
- Stochastic Oscillator
- SKIN 43.48
- NVRO 93.20
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets, and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.